{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:45:01Z","timestamp":1788245101637,"version":"build-2803163510"},"reference-count":34,"publisher":"Tech Science Press","issue":"6","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":143,"URL":"https:\/\/doi.org\/10.32604\/TSP-CROSSMARKPOLICY"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OR"],"published-print":{"date-parts":[[2024]]},"DOI":"10.32604\/or.2024.048919","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T09:11:37Z","timestamp":1714986697000},"page":"1021-1030","update-policy":"https:\/\/doi.org\/10.32604\/tsp-crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["New insights into ATR inhibition in muscle invasive bladder cancer: The role of apolipoprotein B mRNA editing catalytic subunit 3B"],"prefix":"10.32604","volume":"32","author":[{"given":"HYUNHO","family":"KIM","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"UIJU","family":"CHO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SOOK HEE","family":"HONG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HYUNG SOON","family":"PARK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"IN-HO","family":"KIM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HO JUNG","family":"AN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BYOUNG YONG","family":"SHIM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JIN HYOUNG","family":"KANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"17807","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2023 guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"European Urology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/14656566.2022.2150966","article-title":"Perspectives on the future of urothelial carcinoma therapy: Chemotherapy and beyond","volume":"24","author":"Bianchi","year":"2023","journal-title":"Expert Opinion Pharmacotherapy"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jare.2021.11.010","article-title":"Emerging strategies for the improvement of chemotherapy in bladder cancer: Current knowledge and future perspectives","volume":"39","author":"Liu","year":"2022","journal-title":"Journal of Advanced Research"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): A multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"The Lancet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): A randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"The Lancet Oncology"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"108927","DOI":"10.1016\/j.clim.2022.108927","article-title":"Optimal first-line treatment for platinum-eligible metastatic urothelial carcinoma: Comparison of chemo-immunotherapy, immunotherapy, and chemotherapy\u2013A systematic review and meta-analysis","volume":"236","author":"Li","year":"2022","journal-title":"Clinical Immunology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: Results from the JAVELIN bladder 100 trial after \u22652 years of follow-up","volume":"41","author":"Powles","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"100296","DOI":"10.1016\/j.ctarc.2020.100296","article-title":"Role of immunotherapy in bladder cancer","volume":"26","author":"Rhea","year":"2021","journal-title":"Cancer Treatment Research Communications"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nrc3916","article-title":"Replication stress and cancer","volume":"15","author":"Gaillard","year":"2015","journal-title":"Nature Reviews Cancer"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.yexcr.2014.09.030","article-title":"DNA replication stress: Causes, resolution and disease","volume":"329","author":"Mazouzi","year":"2014","journal-title":"Experimental Cell Research"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"107518","DOI":"10.1016\/j.pharmthera.2020.107518","article-title":"Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy","volume":"210","author":"Gorecki","year":"2020","journal-title":"Pharmacology & Therapeutics"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"e0266476","DOI":"10.1371\/journal.pone.0266476","article-title":"Ataxia telangiectasia and Rad3-related inhibition by AZD6738 enhances gemcitabine-induced cytotoxic effects in bladder cancer cells","volume":"17","author":"Isono","year":"2022","journal-title":"PLoS One"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/1535-7163.MCT-20-1026","article-title":"Novel and highly potent ATR inhibitor M4344 kills cancer cells with replication stress, and enhances the chemotherapeutic activity of widely used DNA damaging agents","volume":"20","author":"Jo","year":"2021","journal-title":"Molecular Cancer Therapeutics"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1021\/acs.jmedchem.0c00369","article-title":"Damage incorporated: Discovery of the potent, highly selective, orally available ATR inhibitor BAY 1895344 with favorable pharmacokinetic properties and promising efficacy in monotherapy and in combination treatments in preclinical tumor models","volume":"63","author":"L\u00fccking","year":"2020","journal-title":"Journal of Medicinal Chemistry"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","article-title":"The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models","volume":"19","author":"Wengner","year":"2020","journal-title":"Molecular Cancer Therapeutics"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/jamaoncol.2021.3441","article-title":"Effect of cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma: A phase 2 randomized clinical trial","volume":"7","author":"Pal","year":"2021","journal-title":"JAMA Oncology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1470-2045(20)30180-7","article-title":"Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: A multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Konstantinopoulos","year":"2020","journal-title":"The Lancet Oncology"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.18632\/oncotarget.23344","article-title":"APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response","volume":"9","author":"Glaser","year":"2018","journal-title":"Oncotarget"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/ng.2702","article-title":"An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers","volume":"45","author":"Roberts","year":"2013","journal-title":"Nature Genetics"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.3389\/fmicb.2018.02088","article-title":"APOBEC3B activity is prevalent in urothelial carcinoma cells and only slightly affected by LINE-1 expression","volume":"9","author":"Jaguva Vasudevan","year":"2018","journal-title":"Frontiers in Microbiology"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1158\/0008-5472.CAN-16-3389","article-title":"APOBEC3A and APOBEC3B activities render cancer cells susceptible to ATR inhibition","volume":"77","author":"Buisson","year":"2017","journal-title":"Cancer Research"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1158\/2159-8290.CD-20-0725","article-title":"Induction of APOBEC3 exacerbates DNA replication stress and chromosomal instability in early breast and lung cancer evolution","volume":"11","author":"Venkatesan","year":"2021","journal-title":"Cancer Discovery"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.3390\/curroncol28030154","article-title":"Prognostic impact of APOBEC3B expression in metastatic urothelial carcinoma and its association with tumor-infiltrating cytotoxic T cells","volume":"28","author":"Kim","year":"2021","journal-title":"Current Oncology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/ijc.34228","article-title":"The causal association between smoking, alcohol consumption and risk of bladder cancer: A univariable and multivariable Mendelian randomization study","volume":"151","author":"Xiong","year":"2022","journal-title":"International Journal of Cancer"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.7150\/thno.73235","article-title":"APOBEC-mediated mutagenesis is a favorable predictor of prognosis and immunotherapy for bladder cancer patients: Evidence from pan-cancer analysis and multiple databases","volume":"12","author":"Shi","year":"2022","journal-title":"Theranostics"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41571-018-0026-y","article-title":"Treatment resistance in urothelial carcinoma: An evolutionary perspective","volume":"15","author":"Vlachostergios","year":"2018","journal-title":"Nature Reviews Clinical Oncology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"102925","DOI":"10.1016\/j.bioorg.2019.102925","article-title":"Cisplatin: The first metal based anticancer drug","volume":"88","author":"Ghosh","year":"2019","journal-title":"Bioorganic Chemistry"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41573-022-00558-5","article-title":"Targeting replication stress in cancer therapy","volume":"22","author":"da Costa","year":"2023","journal-title":"Nature Reviews Drug Discovery"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"6042334","DOI":"10.1155\/2022\/6042334","article-title":"APOBEC3B and CD274 as combined biomarkers for predicting response to immunotherapy in urothelial carcinoma of the bladder","volume":"2022","author":"Zhang","year":"2022","journal-title":"Journal of Oncology"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3390\/cells10040759","article-title":"Nuclear translocation of SRPKs is associated with 5-FU and cisplatin sensitivity in HeLa and T24 cells","volume":"10","author":"Sigala","year":"2021","journal-title":"Cells"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41586-022-04972-y","article-title":"Mechanisms of APOBEC3 mutagenesis in human cancer cells","volume":"607","author":"Petljak","year":"2022","journal-title":"Nature"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/iju.14686","article-title":"Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab","volume":"28","author":"Kato","year":"2021","journal-title":"International Journal of Urology"}],"container-title":["Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.techscience.com\/files\/or\/2024\/TSP_OR-32-6\/OncolRes-32-06-48919\/OncolRes-32-48919.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T09:21:24Z","timestamp":1741252884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v32n6\/56599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024]]},"published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.32604\/or.2024.048919","relation":{},"ISSN":["1555-3906"],"issn-type":[{"value":"1555-3906","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"2023-12-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-23","order":2,"name":"published","label":"Published Online","group":{"name":"publication_history","label":"Publication History"}}]}}